Renalytix (RENX) – Press Releases
-
Renalytix Announces Financing with Expected Size of up to $4 Million
-
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
-
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
-
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix
-
Renalytix Reports Full Year Fiscal 2023 Results
-
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28
-
Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer
-
Renalytix Announces Middle East Distribution Agreement with Vector Pharma
-
Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions
-
FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease
-
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
-
Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9
-
New Published Real-World Evidence Shows KidneyIntelX™ Utility
-
Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting
-
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
-
Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30
-
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
Renalytix announces a c.$20.3 million private placement
-
Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States
-
Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems
-
Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes
-
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023
-
Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease
-
Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30
-
Renalytix to Present at Stifel Healthcare Conference
-
Renalytix Reports Full Year Fiscal 2022 Results
-
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31
-
KidneyIntelX Clinical Utility and Health Economics Validated in Multiple Data Releases at American Society of Nephrology
-
Renalytix Announces Change to Board of Directors
-
Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference
-
Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care Physicians
-
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022
-
Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30
-
1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients
-
Renalytix to Present at 42nd Annual William Blair Growth Stock Conference
-
KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort
-
Renalytix Announces Two Data Presentations on KidneyIntelX™ at American Diabetes Association 82nd Scientific Sessions®
-
AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors
-
Renalytix plc Issue of shares
-
Renalytix plc successful completion of $30.0 million financing package
-
Renalytix announces a $30.0 million financing package
-
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
-
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors
-
Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes
-
Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31
-
Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform
-
KidneyIntelX™ Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of Care
-
Renalytix to Present at Cowen 42nd Annual Health Care Conference
-
Renalytix to Appoint Timothy Scannell to Board of Directors
Back to RENX Stock Lookup
